A European benchmarking system to evaluate in-hospital mortality rates in acute coronary syndrome: The EURHOBOP project by Dégano, IR et al.
International Journal of Cardiology 182 (2015) 509–516
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdA European benchmarking system to evaluate in-hospital mortality rates
in acute coronary syndrome: The EURHOBOP project☆Irene R. Dégano a,1, Isaac Subirana a,b,1, Marina Torre c, María Grau a, Joan Vila a,b, Danilo Fusco d,
Inge Kirchberger e,f, Jean Ferrières g, Antti Malmivaara h, Ana Azevedo i, Christa Meisinger e,f, Vanina Bongard j,
Dimitros Farmakis k, Marina Davoli d, Unto Häkkinen h, Carla Araújo i, John Lekakis k, Roberto Elosua a,
Jaume Marrugat a,⁎, on behalf of the EURHOBOP investigators
a REGICOR Study Group, Cardiovascular Epidemiology and Genetics Group, IMIM, Hospital del Mar Medical Research Institute, Barcelona, Spain
b CIBER Epidemiology and Public Health, Spain
c Istituto Superiore di Sanità, Rome, Italy
d Dipartimento di Epidemiologia ASL RME, Rome, Italy
e MONICA/KORA Myocardial Infarction Registry, Augsburg, Germany
f Helmholtz Zentrum München, German Research Center for Environmental Health, Institute for Epidemiology II, Neuherberg, Germany
g Department of Cardiology, Toulouse Rangueil Hospital, Toulouse University School of Medicine, Toulouse, France
h Centre for Health and Social Economics, Helsinki, Finland
i Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Institute of Public Health of the University of Porto (ISPUP), Porto, Portugal
j Department of Epidemiology, UMR 1027 INSERM, Toulouse University, Toulouse, France
k ATTIKON Hospital, University of Athens Medical School, Athens, Greece☆ All authors take responsibility for all aspects of the reli
the data presented and their discussed interpretation.
⁎ Corresponding author at: Carrer Dr Aiguader 88, E-08
E-mail address: jmarrugat@imim.es (J. Marrugat).
1 Both authors have equally contributed to this manusc
http://dx.doi.org/10.1016/j.ijcard.2015.01.019
0167-5273/© 2015 Elsevier Ireland Ltd. All rights reserveda b s t r a c ta r t i c l e i n f oArticle history:
Received 27 August 2014
Received in revised form 30 December 2014
Accepted 4 January 2015
Available online 7 January 2015
Keywords:
Benchmarking
Hospital performance
Acute myocardial infarction
Percutaneous coronary intervention
In-hospital mortality
Background:Hospital performancemodels in acutemyocardial infarction (AMI) are useful to assess patient man-
agement. While models are available for individual countries, mainly US, cross-European performance models
are lacking. Thus, we aimed to develop a system to benchmark European hospitals in AMI and percutaneous cor-
onary intervention (PCI), based on predicted in-hospital mortality.
Methods and results:Weused the EURopeanHOspital Benchmarking byOutcomes in ACS Processes (EURHOBOP)
cohort to develop themodels, which included 11,631 AMI patients and 8276 acute coronary syndrome (ACS) pa-
tients who underwent PCI. Models were validated with a cohort of 55,955 European ACS patients. Multilevel lo-
gistic regression was used to predict in-hospital mortality in European hospitals for AMI and PCI. Administrative
and clinical models were constructed with patient- and hospital-level covariates, as well as hospital- and
country-based random effects. Internal cross-validation and external validation showed good discrimination at
the patient level and good calibration at the hospital level, based on the C-index (0.736–0.819) and the concor-
dance correlation coefﬁcient (55.4%–80.3%). Mortality ratios (MRs) showed excellent concordance between
administrative and clinical models (97.5% for AMI and 91.6% for PCI). Exclusion of transfers and hospital stays
≤1 day did not affect in-hospital mortality prediction in sensitivity analyses, as shown by MR concordance
(80.9%–85.4%). Models were used to develop a benchmarking system to compare in-hospital mortality rates of
European hospitals with similar characteristics.
Conclusions: The developed system, based on the EURHOBOPmodels, is a simple and reliable tool to compare in-
hospital mortality rates between European hospitals in AMI and PCI.© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Acute coronary syndrome (ACS) is the leading cause of morbi-
mortality in Europe, emphasising the need of assessing ACS qualityability and freedom from bias of
003 Barcelona, Spain.
ript.
.of care [1]. To assess quality of care in ACS, it would be useful to an-
alyse hospital performance based on quality indicators; such as
structure (e.g. access to cardiovascular specialists), process (e.g.
timely and appropriate reperfusion) and outcomes (e.g. death)
[2]. Compared to structure and process, outcome indicators pro-
vide a more global measure of quality of care and are the most rel-
evant to patients and physicians [2,3]. In addition, mortality — the
most widely used outcome — has been recommended as a key
indicator of the quality of acute myocardial infarction (AMI) man-
agement [4].
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hospital performance in ACS management based on in-hospital or 30-
daymortality [5–10]. Krumholz et al. provided the ﬁrstmodel to estimate
AMI 30-day mortality for benchmarking purposes, using administrative
data [5]. Following similarmethodology, other authors developedmodels
to estimate AMI [6–8], ACS [9], and percutaneous coronary intervention
(PCI) [10] mortality, mainly using administrative data.
The usefulness of hospital performance models for quality of care
improvement is based on the actions that would be implemented as a
result of the information obtained. For example, it would be expected
that a hospital/department whose AMI mortality is higher than the
mortality observed in other units with similar characteristics, regarding
patients and resources, would revise and improve their current AMI
protocols. Thus, European hospitals, cardiovascular departments and
coronary units must be able to compare themselves to others with sim-
ilar characteristics. For this comparison to be reliable, the data used to
develop the models should be representative of European hospitals.
However, the available models were mainly developed in the US [5,7,
8,10] and most of them, including the only PCI model, were developed
for patients older than 64 years [5,8,10]. In addition, cross-European
performance models, which would be representative of European
hospitals and would allow a common strategy for ACS quality of care
improvement in Europe, are lacking. To ﬁll this gap, we designed the
EURopean HOspital Benchmarking by Outcomes in ACS Processes
(EURHOBOP) project [11]. The EURHOBOP, was a cohort study
funded by the European Commission, designed to provide a valid
ACS benchmarking system to the European Community. The goal of
this system was to allow cardiologists and other professionals from
European hospitals to easily monitor their outcomes in key ACS diag-
nosis and procedures.
The aim of the present study was to derivate and validate a set of
models to benchmark in-hospital mortality rates in European hospitals,
in AMI and PCI, taking into account the country as well as hospital and
patient characteristics. The secondary aim was to provide a computer-
based tool, using the developed models, to allow cardiologists to com-
pare the data from their own practice with others.
2. Methods
The EURHOBOP Study complies with the Declaration of Helsinki andwas approved by
the ethics committee of the Parc de Salut Mar (IMIM-PSMAR 2010/3779/I) of Barcelona,
Spain.
2.1. Data collection
The EURHOBOP cohort included 15,170 ACS patients from 68 hospitals located in:
Finland, France, Germany, Greece, Italy, Portugal, and Spain. Data collection in the
EURHOBOP study has been previously described [12]. Brieﬂy, at least 2000 patients wereTable 1
Comparison of patients from the derivation and the validation cohort.
AMI
Validation Derivation Over
N = 54,083 N = 11,631
Age; mean (SD) 69.0 (13.4) 67.7 (13.6) b0.0
Sex: Female 17,972 (33.2%) 3599 (30.9%) b0.0
Hypertension 14,015 (25.9%) 6100 (52.4%) 0.0
Diabetes 7856 (14.5%) 2904 (25.0%) b0.0
Past history of CVD 14,348 (26.5%) 3819 (32.8%) b0.0
ACS b0.0
Non-STEACS 28,033 (52.2%) 5366 (46.6%)
STEACS 23,643 (44.0%) 5530 (48.1%)
Non classiﬁable 2074 (3.86%) 607 (5.28%)
Shock/pulmonary oedema 1905 (3.53%) 831 (7.14%) b0.0
Renal failure 4150 (8.28%) 1197 (10.3%) b0.0
In-hospital mortality 4469 (8.26%) 868 (7.46%) 0.0
Unless indicated represented values are: frequencies (percentages).
AMI: acute myocardial infarction; PCI: percutaneous intervention; SD: standard deviation; CV
elevation.retrospectively recruited per country from 2008 to 2012, with a mean of 221 consecutive
patients recruited per hospital. Patient- and hospital-level data were obtained from the
letter of discharge and from medical records (whether on paper or electronic). Patient
characteristics included demographic variables, cardiovascular (CV) risk factors, comor-
bidities, procedures and complications during hospitalization, and admission and dis-
charge data. Hospital characteristics included the number of beds and cardiology
patients discharged, as well as ACS care facilities. Collected variables are listed in the Sup-
plementary material online, Table S1.
2.2. Study population and outcome
EURHOBOPpatientswith a discharge diagnosis of unstable angina (UA) or AMI (Inter-
national Classiﬁcation of Diseases 10th revision: I21.0–I21.9 and I20.0) were selected for
the present study. Two patient subsets were chosen for hospital benchmarking due to
their importance in ACSmanagement: patients with a discharge diagnosis of AMI and pa-
tients who underwent PCI during the index admission. Patients from hospitals that re-
cruited less than 10 patients for any of the subsets were excluded from the analysis. The
ﬂowchart of the included patients is presented in Fig. S1. The selected outcome was in-
hospital mortality from any cause during the index admission.
2.3. Candidate variables
Variables predictive of in-hospital mortality were chosen based on literature evidence
and clinical experience. Candidate variables for analysis were selected on the basis of the
reference time (deﬁned as admission), as suggested formodels reporting health outcomes
[13]. Thirteen candidate variables remained for the analysis: 8 at the patient level (age,
sex, hypertension, diabetes, past history of CV diseases, ACS type, presence of cardiogenic
shock or acute pulmonary oedema on admission and presence of renal failure on admis-
sion), and 5 at the hospital level (presence of intensive care unit (ICU), coronary care
unit (CCU), catheterization laboratory, cardiac surgery, and university hospital status).
Two sets of variables were deﬁned: a clinical set, containing all candidate variables, and
an administrative set, excluding the presence of cardiogenic shock or acute pulmonary oe-
dema and the presence of renal failure on admission.
2.4. Model description
Two hierarchical logistic mixed models, one with the clinical and the other with the
administrative set of variables, were ﬁtted to each patient subset (AMI or PCI). In-
hospital mortality was the binary outcome variable; patient and hospital characteristics
constituted the ﬁxed-effect explanatory variables. Hospital and country were also includ-
ed as random-effect variables to deal with the hierarchical clustering of data.
2.5. Expected in-hospital mortality calculation
To calculate the expected in-hospital mortality the model was ﬁtted using all patients
except those admitted to the hospital for which the expected in-hospital mortality was
being computed. This procedure, also known as cross-validation was repeated for all hos-
pitals. Two types of expected in-hospital mortality rates were computed: (i) for hospitals
located in countries included in the sample, by including the speciﬁc country effect in the
model, and (ii) for hospitals from other countries, using the same hospitals data but as-
suming that they were from a country not included in the sample and setting the country
effect to zero. Methodological detail regarding the computation of expected in-hospital
mortality rates is provided in the Supplementary material online.PCI
all p-value Validation Derivation Overall p-value
N = 25,747 N = 8276
01 65.2 (12.5) 64.6 (12.6) b0.001
01 6500 (25.2%) 2050 (24.8%) 0.392
00 6336 (24.6%) 4364 (52.7%) 0.000
01 3139 (12.2%) 1841 (22.2%) b0.001
01 6018 (23.4%) 2679 (32.4%) b0.001
01 b0.001
10,696 (41.8%) 3848 (47.0%)
14,505 (56.6%) 4002 (48.8%)
409 (1.60%) 343 (4.19%)
01 695 (2.70%) 400 (4.83%) b0.001
01 1274 (5.54%) 543 (6.56%) 0.001
04 977 (3.79%) 278 (3.36%) 0.073
D: cardiovascular disease; ACS: acute coronary syndrome; STEACS: ACS with ST segment
Table 2
Characteristics of the participating hospitals in the derivation cohort.
ICU CCU Cath Lab Cardiac University Total
ICU: intensive care unit 61 55 54 32 29 61
CCU: coronary care unit 55 59 54 33 29 59
Cath Lab: catheterization
laboratory
54 54 55 33 29 55
Cardiac: cardiac surgery 32 33 33 33 25 33
University: university hospital 29 29 29 25 30 30
Pairwise combinations and marginal frequencies for the included hospital characteristics
in the 68 participating hospitals.
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A forward stepwise procedurewas used to select the variables included in themodels
from the list of candidate variables. The selection was based on the maximization of the
concordance correlation coefﬁcient (CCC). The CCC was computed as the agreement be-
tween observed and expected in-hospital mortality rates for each hospital, weighted for
the number of patients recruited by that hospital. Expected and observed mortality rates
were normalized with the squared-sinus transformation prior to CCC calculation. The
step-forward process was repeated until all candidate variables were included (Fig. S2).
An extra step was conducted to remove the variables that did not improve the CCC and
were not signiﬁcantly associated with the outcome. Sex was forced into the AMI models
to account for the demographic and clinical differences between men and women with
an AMI. Due to the high co-linearity of the ICU, CCU and catheterization laboratory vari-
ables, if one of these entered in the model, the other two were removed from the list of
candidate variables.
2.7. Model validation
Model validation was assessed internally and externally using two measures: the C-
index, to assess model discrimination at the patient level, and the CCC between observed
and expected rates, to assessmodel calibration at the hospital level. The CCCwas provided
together with its 95% conﬁdence interval and an “upper reference value”, which was cal-
culated under the hypothesis that, with our sample size, the variables explained 100% of
the observed variability. Internal validation was performed by cross-validation as
described in Section 2.5. External validation was performed using an independent cohort
of 55,955 ACS patients who were included in 3 European registries: the Cooperative
Health Research in the Region of Augsburg (KORA) Myocardial Infarction Registry
(2005–2011, n = 3973) [14], the Lazio Region Hospital Information System
(2008–2013, n = 44,855) [15] and the Spanish MASCARA ACS Study (2004–2005, n =
7127) [16]. Hospitals with less than 10 patients in any of the analysed subsets were
excluded.Table 3
Derivation and validation of administrative and clinical models.
AMI
Clinical
N = 11,503
Adminis
N = 11,5
Included variables OR [95% CI]
Sex: Female 0.98 [0.83–1.15] 1.04 [0.8
Age 1.07 [1.06–1.08] 1.07 [1.0
Hypertension 0.65 [0.55–0.78] 0.69 [0.5
Diabetes 1.30 [1.08–1.55] 1.45 [1.2
Past history of CVD 1.14 [0.9
ACS: STEACS 3.23 [2.70–3.86] 3.00 [2.5
ACS: Non classiﬁable 2.73 [2.05–3.62] 2.99 [2.2
Shock/pulmonary oedema 6.92 [5.68–8.43]
Renal failure 2.07 [1.68–2.54]
CCU/ICU 0.48 [0.28–0.85] 0.42 [0.2
Catheterization laboratory
University hospital
Internal cross-validation
C-index [95% CI] 0.819 [0.805, 0.834] 0.773 [0
CCC% [95% CI] 65.2 [49.6,75.6] 63.1 [48
CCC upper reference value% 85.3 84.3
External validation
C-index [95% CI] 0.807 [0.800, 0.814] 0.751 [0
CCC% [95% CI] 53.6 [35.5,61.8] 50.9 [37
CCC upper reference value% 92.1 91.8
For each variable, the Odds ratio and its 95% conﬁdence interval are presented for themodel ﬁtt
tion; OR: odds ratio; CI: conﬁdence interval; CVD: cardiovascular disease; ACS: acute coronary s
care unit; CCC: concordance correlation coefﬁcient.2.8. Concordance between administrative and clinical models
Administrative and clinical models were compared by assessing the concordance of
mortality ratios (MRs) [5,10] for eachmodel type. MRs were computed as the ratio of pre-
dicted and expected in-hospital mortality rates in each hospital. The predicted in-hospital
mortality rates were calculated as the expected rates, described in Section 2.5, but adding
the speciﬁc effect of each hospital. MRs were log-transformed for normalization. Log-MRs
from administrative and clinical models were compared for each patient subset (AMI and
PCI) using the CCC statistic. Methodological detail regarding the computation of predicted
in-hospital mortality rates is provided in the Supplementary material online.
2.9. Sensitivity analyses
The four described models were re-ﬁtted on a subsample, excluding transferred pa-
tients and patients who stayed ≤1 day at the hospital. The ﬂowchart of the included pa-
tients is presented in Fig. S3. Cross-validation was performed with the C-index and CCC
measures. MRs were calculated for eachmodel as described and log-MRs were compared
to the log-MRs from the full sample using the CCC.
Statistical analysis was performed with R Statistical Package (R Foundation for Statis-
tical Computing, Vienna, Austria; Version 3.0.2) [17].
3. Results
3.1. Patient and hospital characteristics
In the derivation cohort patients had amean age of 66 years and 28%
were women. Patient characteristics by subset are presented in Table 1.
Crude in-hospitalmortality was 7.5% in AMI patients and 3.4% in the pa-
tients who underwent PCI. From the included cases, 25.7% and 19.6% in-
volved hospital transfers in theAMI and the PCI subset, respectively. The
proportion of patients discharged within the ﬁrst 24 h was 8.2% in the
AMI subset and 5.5% in the PCI subset.
Regarding hospital characteristics, more than 75% of the hospitals
had ICU, CCU, or catheterization laboratory, or a combination of these fa-
cilities. Around 50% of the hospitals had cardiac surgery facilities or
were university hospitals (Table 2).
3.2. Model derivation
The administrative and clinical AMI models included the following
predictor variables: sex, age, hypertension, diabetes, ACS type, andPCI
trative
03
Clinical
N = 8192
Administrative
N = 8192
8–1.21]
6–1.08] 1.07 [1.05–1.08]
8–0.82] 0.77 [0.57–1.03]
2–1.72] 1.26 [0.92–1.72] 1.37 [1.02–1.85]
7–1.34] 1.56 [1.17–2.06] 1.31 [1.00–1.73]
2–3.56] 5.89 [4.17–8.31] 6.50 [4.66–9.06]
9–3.92] 1.90 [0.94–3.81] 2.38 [1.22–4.65]
14.0 [10.3–19.1]
1.92 [1.27–2.91]
5–0.71]
2.18 [1.01–4.71] 2.21 [1.05–4.65]
1.22 [0.86–1.73] 1.33 [0.96–1.84]
.757, 0.788] 0.812 [0.785, 0.840] 0.800 [0.775, 0.826]
.7,73.5] 58.3 [48.0,64.3] 56.8 [47.3,64.3]
72.6 71.7
.744, 0.759] 0.745 [0.727, 0.762] 0.736 [0.720, 0.753]
.5,61.1] 47.8 [14.9,56.1] 42.1 [22.8,52.9]
81.2 75.7
ed in the derivation cohort. AMI: acutemyocardial infarction; PCI: percutaneous interven-
yndrome; STEACS: ACSwith ST segment elevation; CCU: coronary care unit; ICU: intensive
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acute pulmonary oedema and renal failure on admission, while the ad-
ministrativemodel included previous history of CV disease instead. Age,
diabetes, ACS type, cardiogenic shock/acute pulmonary oedema and
renal failure on admission were positively associated with in-hospital
mortality. Hypertension and presence of CCU/ICUwere negatively asso-
ciated with the outcome.
As for PCI, both the administrative and clinical models included the
following predictor variables: diabetes, past history of CV disease, ACS
type, catheterization laboratory and university hospital (Table 3). The
clinical model included also cardiogenic shock/acute pulmonary oedema
and renal failure on admission, while the administrative model included
age and hypertension instead. All variables, except for hypertension,
were positively associated with in-hospital mortality.
Most of the variables included in the AMI and PCI models had a sig-
niﬁcant or borderline association with in-hospital mortality at the pa-
tient level. In the clinical models, the variable with a larger effect onFig. 1. Concordance between observed and expected in-hospital mortality rates. Concordance
(right) in the AMI (top) and PCI subsets (bottom). Dot size is proportional to the number of
(Ref.) are provided for each scenario.in-hospital mortality was cardiogenic shock/pulmonary oedema on ad-
mission; in the administrative models, it was ACS type.
3.3. Model validation
Internal cross-validation showed good discrimination at the patient
level of AMI models (c-statistic = 0.819 and 0.773 for clinical and ad-
ministrative models, respectively) and PCI models (c-statistic = 0.812
and 0.800, respectively) (Table 3). At the hospital level, models showed
robust calibration (CCC/upper reference = 76.4% and 74.9%, for AMI
clinical and administrativemodels, respectively; CCC/upper reference=
80.3% and 79.2%, for PCI models, respectively) (Table 3, Fig. 1).
Performance was also analysed assuming that in-hospital mortality
rates were predicted for hospitals located in countries not included in
the sample. In this scenario, model discrimination was satisfactory for
AMI clinical and administrative models (c-statistic = 0.800 and 0.747,
respectively) as well as for PCI models (c-statistic = 0.771 and 0.771,of in-hospital mortality rates analysed with the clinical (left) and administrative models
patients included by hospital (legend). The CCC, its 95% CI, and its upper reference value
Fig. 2. Concordance between hospital MRs obtained with administrative and clinical
models. Concordance of log-MRs analysed in the AMI (top) and PCI subsets (bottom).
Dot size is proportional to the number of patients included by hospital (legend). The
CCC and its 95% CI are provided for each subset.
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PCI models (CCC/upper reference = 21% for AMI models, and 15% and
23%, for PCI clinical and administrative models, respectively).
External validation was performed with the validation cohort sum-
marized in Table 1. The proportion of patients with cardiovascular risk
factors, and with renal failure and killip classes III–IV on admission,
was lower in the validation cohort compared to the derivation cohort
(Table 1). In AMI models, all explanatory variables showed similar ORs
in the derivation and validation cohort, except for hypertension and
CCU/ICU. However, in PCI models, ORs differed in both cohorts for hy-
pertension, diabetes, past history of cardiovascular disease, ACS type
and catheterization laboratory (Tables 1 and S3). Model discrimination
was good in the validation cohort (c-statistic = 0.736–0.807), and did
not differ between the derivation and the validation cohort except for
PCImodels (Table 3).Model calibrationwas acceptable in the validation
cohort (CCC/upper reference= 55.4–58.9%) and did not differ between
the derivation and the validation cohort (Table 3 and Fig. S5).
3.4. Concordance between administrative and clinical models
Themean in-hospitalMRmultiplied by the crude in-hospitalmortal-
ity was 7.58% (SD = 1.50) for patients diagnosed with AMI and 3.23%
(SD=0.84) for patients who underwent PCI. The concordance between
the log-MRs obtained from administrative and clinical models was ex-
cellent for AMI and PCI models (97.5% and 91.6%, respectively) (Fig. 2).
3.5. Sensitivity analysis
Model re-ﬁtting in a subsample excluding transfers and hospital stays
≤1 day yielded similar ORs for all explanatory variables at the patient
level, except for diabetes in the PCI administrative model (Tables 3 and
S2). Regarding hospital level variables, neither CCU/ICU had an effect on
in-hospitalmortality in theAMI clinicalmodel, nor catheterization labora-
tory in the PCI models. No difference was observed in model discrimina-
tion and calibration in AMI models. On the other hand, PCI models
showed similar discrimination but lower calibration (CCC/reference =
59.4% and 61.2%, for clinical and administrative models, respectively)
(Table S2, Fig. S4). Importantly, there was a high concordance between
the log-MRs obtained in the whole sample and in the sensitivity analysis
subsample: 82.7% and 80.9% for AMI clinical and administrative models,
and 85.4% and 84.3% for PCI clinical and administrative models (Fig. 3).
3.6. Computer-based tool
The developed models were implemented as an on-line application
to provide a straightforward tool to compare AMI/PCI in-hospital mor-
tality rates from cardiology units and hospitals with others. The on-
line application can be accessed from the EURHOBOP website [11], by
clicking on the Hospital benchmarking icon. Once in the application, a
description of the tool is provided and a page for data entry appears.
After sending the data the application produces the percentile distribu-
tion of the expected in-hospital mortality rates in all EURHOBOP hospi-
tals with similar characteristics and the location of the assessed hospital
in this distribution (Fig. 4).
4. Discussion
We developed a benchmarking system to compare performance of
European hospitals and cardiology units in AMI management and PCI
use. Our system is based on in-hospitalmortality predicted at the hospi-
tal level bymultilevel logistic regressionmodels. The developedmodels
allow cardiologists and other professionals in the cardiology ﬁeld to
compare their own data with others with similar characteristics even
if only administrative data is available.
Patient-level variables included in our models were also retained in
previous models with similar effects [5–10]. In addition, prior AMI andPCI models included more comorbidities, admission and procedural
variables [5–8], which were not included in our models due to non-
availability, presence of missing values or non-compliance with the ref-
erence time. Regarding hospital-level variables, only the AMI model by
Seghieri et al. includedone, catheterization laboratory [6], whichdid not
contribute signiﬁcantly to our AMI models, even if CCU/ICU was re-
moved from the list of candidate variables. However, catheterization
laboratory was the main hospital-level variable in our PCI models.
CCU/ICU was negatively associated with in-hospital mortality in our
AMI models, while catheterization laboratory was positively associated
with in-hospital mortality in our PCI models. This apparent discrepancy
is probably showing — through the CCU/ICU variable — the positive
correlation of larger and better-equipped hospitals with in-hospital
mortality [18]. At the same time, catheterization laboratory would be
representing the negative correlation between time to reperfusion and
514 I.R. Dégano et al. / International Journal of Cardiology 182 (2015) 509–516in-hospital mortality [19,20], as its effect disappeared when transferred
patients were excluded.
Model discrimination at the patient level was similar between our
models and those reported in previous studies [5–10]. Our AMI models
showed a C-index of 0.77 and 0.82 for administrative and clinical
models, respectively. In previous studies, discrimination of AMI models
ranged from 0.70 to 0.83 for administrative models and from 0.77 to
0.84 for clinical models [5–8]. As for PCI, the C-index of our clinical
model was 0.81, similar to the discrimination capacity of the only PCI
model — clinical — for hospital benchmarking to date (0.84) [10].
The obtained MRs were consistent with previous studies: a mean of
7.58% for AMI patients compared to AMI in-hospital and 30-day in-
hospital mortality rates of 8.10% and 7.99%, respectively [6,7]. As for
PCI, Curtis et al. found an SMR of 1.55%, compared to the 3.23% MR ob-
served in this study [10]; this difference is probably due to the exclusion
of same-day discharges in the Curtis et al. study.Fig. 3. Sensitivity analysis: concordance of MRwhen excluding transfers and hospital stays≤1 d
analysed with the clinical (left) and administrative models (right) in the AMI (top) and PCI s
(legend). The CCC and its 95% CI are provided for each scenario.It has been suggested that non-standardized periods of assessment,
such as the hospitalization interval, may result in a biased evaluation of
hospital performance due to varying lengths of stay (LOS) and transfer
of patients [13]. Mean LOS in AMI patients is positively correlated with
in-hospital SMR [21], while inter-hospital transfers of AMI patients
affects 30-day SMR in acute-care hospitals [22] but not in non-
procedure hospitals [23]. On the other hand, it has been argued that
hospitals are only responsible for events that occur within their institu-
tion [24]. In this study,we found that 19.6% to 25.7% of the patientswere
transferred and 5.5% to 8.2% of patients had LOS ≤1 day. In contrast to
the current assumption, our study showed good concordance (81%–
86%) between in-hospital log-MR when transfers and short LOS were
excluded or not, indicating that these factors do not bias hospital perfor-
mance assessment based on in-hospital mortalitywhen the appropriate
statistical methodology is used. In addition, excluding transfers may
cause an inaccurate estimation of quality of care in certain hospitals/ay. Concordance between the overall log-MR and those obtained in the sensitivity sample
ubsets (bottom). Dot size is proportional to the number of patients included by hospital
Fig. 4. Percentile distribution of AMI in-hospital mortality rates from the European hospitals of the validation cohort. Output of the on-line application using the characteristics of the val-
idation cohort from Table 1. For this example we have set the benchmarked hospital/unit in Finland. This unit had ICU/CCU but not catheterization laboratory and it was not a university
hospital. The benchmark results shownot only thepercentile distribution of thehospitals but also the location of the analysedunit in this distribution (Hospital case column), aswell as the
performance measures of the model.
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and short LOSwhen comparing in-hospitalmortality from clinical cardi-
ology practice.
Administrative data, which contain important predictors of mortali-
ty [25], are often used for outcomes research. Advantages of administra-
tive data are its availability and reduced cost compared to clinical data.
On the other hand, administrative data may lack certain predictors of
mortality [7]. Two studies demonstrated good correlation between ad-
ministrative and clinical models for hospital proﬁling in AMI [5,7]. A
more appropriate measure to compare administrative and clinical
model is the concordance of their estimates. In this study, we found
an excellent concordance (N90%) between log-MRs obtained with the
administrative and clinical models, especially for AMI (97%). Our ad-
ministrative models may perform better than previous models due to
the model development strategy and to the inclusion of the ACS-type
ﬂag [9]. These results show that using the EURHOBOP models, an accu-
rate comparison of in-hospital mortality can be performed by either
cardiologists or other healthcare professionals provided that at least ad-
ministrative data is available.
The available AMI and PCI models for hospital benchmarking are
intended for public reporting, and assume access to administrative/
clinical data as well as linkage to mortality registries [5–10]. Our
benchmarking system, however, has been designed for cardiologistsand healthcare professionals directly involved in the improvement of ACS
protocols and patientmanagement. Thus, it has been designed as a tool to
improvemanagement of AMI andPCI patients, through the comparisonof
in-hospital mortality rates to the rates from similar hospitals. This
comparison can be performed anonymously, in a few minutes, and by
different users ranging from cardiologists to hospital managers and
other stakeholders, as the only requirement is aggregate data from a sam-
ple of ACS patients and there is the possibility of applying administrative/
clinical models depending on variable availability.
Our study has several strengths. We developed the ﬁrst cross-
European multinational benchmarking models to estimate AMI and PCI
in-hospital mortality rates using up-to-date data. We did not exclude pa-
tients due to age, LOS, or whether they were transferred or not, which al-
lows more representative estimates of in-hospital mortality rates. We
used standard methods for variable selection and statistical analysis,
includingmodel derivation and validation.We suggested ametric to eval-
uate model calibration at the hospital level using the concordance corre-
lation coefﬁcient. And ﬁnally, we developed an on-line application to
obtain the expected distribution of in-hospital mortality rates from simi-
lar hospitals and the location of the assessed hospital/unit in this distribu-
tion. This application is a simple, rapid, and precise tool that can be
employed by a variety of users to gather insight into the comparison of
AMI and PCI in-hospital mortality rates between similar hospitals.
516 I.R. Dégano et al. / International Journal of Cardiology 182 (2015) 509–5165. Study limitations
The main limitation of our study is the difference between the deri-
vation and the validation cohort. The derivation cohort includedACS pa-
tients from 7 countries, while the validation cohort included patients
from 3 of these countries. In addition, both cohorts were signiﬁcantly
different regarding the number of patients per hospital and the charac-
teristics of the patients. Despite these differences, the proposed models
showed good discrimination and acceptable calibration capacity, sug-
gesting that the models perform adequately even if the sample is
completely different from the derivation cohort. Another limitation re-
lates to potentialmissing variables that could impact in-hospitalmortal-
ity rates and variability at the hospital- and country-level, such as
pharmacological treatment in the acute phase. This limitation is related
to the exclusion criteria used and to the goal of providing a simple and
precise tool for hospital benchmarking. To fulﬁl this goal, we had to bal-
ance model parsimony and performance. Finally, we observed that the
CCC was much lower than expected when the country was simulated
as outside the EURHOBOP cohort. The validity of the developed models
in countries other than those included in the study merits additional
research.6. Conclusions
Wepresent a benchmarking system to assess Europeanhospital per-
formance in AMI and PCI, based on predicted in-hospitalmortality rates.
Our models take into account hospital and patient characteristics, as
well as the hospitals' country. Our system allows comparison of in-
hospital mortality rates between European hospitals sharing similar pa-
tient and hospital characteristics, which could be used by cardiologists
to improve their own practices, by hospitals and in a common public
health strategy to improve ACS quality of care in Europe.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2015.01.019.Conﬂict of interest
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